HRT FINANCIAL LP purchased $330K of CMND

HRT FINANCIAL LP purchased 2,159,052 shares of Clearmind Medicine Inc. (CMND) at $0.15 ($0.33M total) on 2026-06-10.

Original reporting
SEC EDGAR · HRT FINANCIAL LP
Published Jun 12, 2026, 8:28 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 12, 2026, 8:34 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$CMND
Bullish
medium confidence
Mentioned
$CMND
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CMNDBullishLow
01

Why it matters

The newest fact is the disclosed purchase size, price ($0.1530/share), and post-transaction holdings for a 10% owner, which can modestly influence sentiment but lacks fundamental new information.

02

Market read

CMND receives a fresh ownership-increase datapoint from a large holder, which may attract short-term attention but is unlikely to drive a durable repricing alone.

03

What to watch

The filing does not disclose intent, valuation rationale, or whether the buy changes future behavior; traders should watch for subsequent Form 4s or company catalysts.

Relevance 5/10Novelty 8/10Timing: SEC Form 4 filed 2026-06-12 (purchase dated 2026-06-10)

Background

The article is an SEC EDGAR Form 4 insider transaction disclosure for Clearmind Medicine Inc. (CMND).

Company-level read

Ticker impact

$CMNDBullishMedium confidence
Context

HRT Financial LP (10% owner) filed an SEC Form 4 open-market purchase of 2,159,052 CMND shares on 2026-06-10.

Expected impact

Near-term impact likely limited; any effect would be sentiment-driven and may fade unless followed by additional disclosures.

Evidence & confidence

Form 4 insider/institutional buying can support sentiment, but the article provides no new company-specific operating/regulatory/financial development beyond the transaction details.

Market effects

No sector-level read-through; this is a single-issuer ownership transaction.

None indicated.

None indicated.

Counterpoint

Open-market buys can be routine (e.g., liquidity/portfolio rebalancing) and may not reflect a new thesis; without a 10b5-1 plan, it still may be non-informational.

Key entities

  • Clearmind Medicine Inc.

    Subject of the Form 4 disclosure; ticker CMND.

  • HRT Financial LP

    Reported open-market purchase of CMND shares; filed the Form 4.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$CMNDMedAI 8/10

Clearmind completes enrollment for CMND-100 trial part C

Clearmind Medicine (CMND) completed patient enrollment for Part C of its Phase I/IIa trial for CMND-100, a treatment for neuropsychiatric and addiction disorders. The trial, conducted in the U.S. and Israel, assesses safety, tolerability, and pharmacokinetics. The company aims to develop non-hallucinogenic psychedelic-derived compounds.

$CMNDLow

Clearmind completes patient recruitment for AUD trial segment

Clearmind Medicine (NASDAQ:CMND) completed patient recruitment for the first segment of Part B in its Phase I/IIa trial of CMND-100 for Alcohol Use Disorder. The trial, involving 12 patients, will assess safety, tolerability, and early efficacy signals. Sites include Johns Hopkins, Yale, and Israeli medical centers. According to the company, this marks a significant step in evaluating CMND-100 in the target patient population.

$CMNDLow

Clearmind has recruited its first group of people with alcohol use disorder for a clinical trial.

Clearmind Medicine (Nasdaq: CMND) has completed patient recruitment for the first segment of Part B of its Phase I/IIa clinical trial for CMND-100, a potential treatment for alcohol use disorder (AUD). The trial, conducted at sites including Johns Hopkins and Yale, will assess safety, tolerability, and early efficacy signals in patients with moderate-to-severe AUD. According to the company, this marks a significant milestone in validating CMND-100's therapeutic potential.

$CMNDMedAI 8/10

Clearmind Medicine Inc.: Clearmind Enrolls First Patients with Alcohol Use Disorder in CMND-100 Clinical Trial

Clearmind Medicine Inc. (Nasdaq: CMND) has enrolled the first patients with Alcohol Use Disorder (AUD) in its CMND-100 clinical trial. The trial, evaluating the safety and efficacy of CMND-100, is being conducted at Hadassah Medical Center in Jerusalem. The company aims to advance its psychedelic-based treatment for AUD, with plans to achieve key clinical milestones. Clearmind's shares are listed on Nasdaq under the symbol 'CMND'.

$CMNDMed

Clearmind Medicine Receives Yale IRB Approval For CMND-100 Trial

Clearmind Medicine (CMND) received Yale IRB approval to expand its Phase I/II trial for CMND-100, a treatment for alcohol use disorder. The trial will now include Yale School of Medicine, adding to sites like Johns Hopkins. CMND-100 showed positive safety results in earlier trials. CMND stock closed at $1.16, down 31.76%, and is trading at $1.12 premarket.

$CMNDMed

Clearmind Tumbles on Buying into Charging Robotics

Clearmind Medicine (CMND) agreed to buy a 51% stake in Charging Robotics, a wireless EV charging solutions provider, for $2.5M. The company will also lend Charging Robotics $1.5M at 4% interest. Charging Robotics' tech offers up to 10 kW continuous charging for automated parking and autonomous vehicles.